Evidence map›Paper›PMID 41884389›Full record

ArticleClinical, cosmetic and investigational dermatology2026

Integrative Multi-Omics and Experimental Analyses Identify TAPBP as a Key Mediator Linking Genetic Susceptibility to Melanocyte Dysfunction in Vitiligo.

Jinlong Shi, Mingzhen Guo, Liying Fu, Jiangman He, Yuan Hu

Abstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinlong Shi *Department of Dermatology, Zhengzhou People's Hospital, Zhengzhou, Henan, People's Republic of China.
Mingzhen Guo *Department of Laboratory, Women and Children's Hospital Affiliated to Qingdao University, Qingdao, Shandong, People's Republic of China.
Liying FuDepartment of Dermatology, Zhengzhou People's Hospital, Zhengzhou, Henan, People's Republic of China.
Jiangman HeDepartment of Dermatology, Zhengzhou People's Hospital, Zhengzhou, Henan, People's Republic of China.
Yuan HuDepartment of Dermatology, Suining Central Hospital, Suining, Sichuan, People's Republic of China.ORCID 0000-0003-2188-5920

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vitiligo is an autoimmune depigmenting disorder characterized by selective melanocyte loss; however, the specific molecular bridges between genetic risk variants and melanocyte-intrinsic immune vulnerability remain largely unexplored. Objective: To elucidate the molecular link between genetic susceptibility and melanocyte injury in vitiligo by integrating multi-omics data. Methods: We integrated large-scale genome-wide association data (FinnGen R12, n=466,064), expression quantitative trait loci (eQTLgen, n=31,684), and single-cell transcriptomic profiles to identify genes mediating vitiligo susceptibility. Results: Cross-omic analysis identified TAPBP as a top candidate, which is significantly upregulated in lesional melanocytes and core to the antigen-processing network. Functional validation in human melanocytes demonstrated that TAPBP overexpression significantly increased HLA class I expression, suppressed cell proliferation, and induced apoptosis. Transcription factor analysis further identified STAT2 as a key upstream regulator, linking interferon signaling to aberrant antigen presentation. Conclusion: These findings suggest that the STAT2-TAPBP axis enhances melanocyte immunogenicity and vulnerability to cytotoxic attack. Our study provides a novel mechanistic link between genetic variation and immune-mediated destruction, positioning TAPBP as a potential biomarker and a target for precision immunotherapy in vitiligo.

Indexed as

antigen presentationmulti-omics integrationTAPBPvitiligo

Identifiers

PMID41884389
PMCPMC13012158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.